DK1743027T3 - Mutantpneumolysinproteiner - Google Patents

Mutantpneumolysinproteiner

Info

Publication number
DK1743027T3
DK1743027T3 DK05742528.2T DK05742528T DK1743027T3 DK 1743027 T3 DK1743027 T3 DK 1743027T3 DK 05742528 T DK05742528 T DK 05742528T DK 1743027 T3 DK1743027 T3 DK 1743027T3
Authority
DK
Denmark
Prior art keywords
mutant pneumolysin
pneumolysin proteins
proteins
mutant
pneumolysin
Prior art date
Application number
DK05742528.2T
Other languages
English (en)
Inventor
Lea-Ann Kirkham
Timothy John Mitchell
Original Assignee
Univ Glasgow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Glasgow filed Critical Univ Glasgow
Application granted granted Critical
Publication of DK1743027T3 publication Critical patent/DK1743027T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267Gram-positive bacteria
    • C07K16/1275Streptococcus (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK05742528.2T 2004-05-07 2005-05-09 Mutantpneumolysinproteiner DK1743027T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56941504P 2004-05-07 2004-05-07
GBGB0410220.8A GB0410220D0 (en) 2004-05-07 2004-05-07 Mutant pneumolysin proteins
PCT/GB2005/001792 WO2005108580A1 (en) 2004-05-07 2005-05-09 Mutant pneumolysin proteins

Publications (1)

Publication Number Publication Date
DK1743027T3 true DK1743027T3 (da) 2013-09-30

Family

ID=32482854

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05742528.2T DK1743027T3 (da) 2004-05-07 2005-05-09 Mutantpneumolysinproteiner

Country Status (15)

Country Link
US (1) US7820789B2 (da)
EP (1) EP1743027B1 (da)
JP (1) JP4848552B2 (da)
KR (1) KR101191591B1 (da)
CN (1) CN101018863B (da)
AU (1) AU2005240835B2 (da)
CA (1) CA2566344C (da)
DK (1) DK1743027T3 (da)
ES (1) ES2427978T3 (da)
GB (1) GB0410220D0 (da)
IL (2) IL178885A (da)
PL (1) PL1743027T3 (da)
PT (1) PT1743027E (da)
SI (1) SI1743027T1 (da)
WO (1) WO2005108580A1 (da)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US9370557B2 (en) * 2006-06-15 2016-06-21 The University Court Of The University Of Glasgow Adjuvant compounds
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
CA2683748C (en) * 2007-04-13 2016-02-16 The Board Of Regents Of The University Of Oklahoma Mutants of cholesterol-dependent cytolysins and uses thereof
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
BRPI0821240B8 (pt) * 2007-12-21 2022-10-04 Novartis Ag formas mutantes de estreptolisina o
US9125863B2 (en) * 2008-05-22 2015-09-08 Children's Medical Center Corporation Synergistic immunogenic fusion protein-polysaccharide conjugate
CN102712680B (zh) * 2008-12-24 2016-06-22 荷兰王国卫生福利和运动部国家公共卫生和环境研究所 修饰的肺炎链球菌溶血素(ply)多肽
US20120064103A1 (en) 2009-03-24 2012-03-15 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
WO2010125480A1 (en) * 2009-04-30 2010-11-04 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
WO2011030218A1 (en) 2009-09-10 2011-03-17 Novartis Ag Combination vaccines against respiratory tract diseases
CN102939105B (zh) * 2009-12-22 2016-11-16 赛诺菲巴斯德有限公司 免疫原性组合物和相关的方法
WO2011075823A1 (en) * 2009-12-22 2011-06-30 Sanofi Pasteur Limited Immunogenic compositions
RU2580620C2 (ru) 2010-08-23 2016-04-10 ВАЙЕТ ЭлЭлСи СТАБИЛЬНЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Neisseria meningitidis rLP2086
WO2012032489A1 (en) 2010-09-10 2012-03-15 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
US9181308B2 (en) 2011-03-28 2015-11-10 St. Jude Children's Research Hospital Methods and compositions employing immunogenic fusion proteins
US20130164774A9 (en) 2011-04-08 2013-06-27 University Of Massachusetts Methods, compositions and kits for assaying mitochondrial function
US9034322B2 (en) * 2011-04-21 2015-05-19 The Rockefeller University Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria
CN108840912B (zh) 2011-05-11 2023-07-04 儿童医疗中心有限公司 修饰的生物素结合蛋白及其融合蛋白和应用
SG194733A1 (en) 2011-05-17 2013-12-30 Glaxosmithkline Biolog Sa Vaccine against streptococcus pneumoniae
ITMI20111182A1 (it) 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
CN104519910B (zh) 2012-03-07 2017-05-03 诺华股份有限公司 肺炎链球菌抗原的含佐剂制剂
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2900008C (en) 2013-02-07 2025-10-07 Children's Medical Center Corporation PROTEIN ANTIGENS THAT CONFER PROTECTION AGAINST COLONIZATION AND/OR PNEUMOCOCCAL DISEASE
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
US11207396B2 (en) 2013-05-17 2021-12-28 The Board Of Regents Of The University Of Texas System Immunization to protect against adverse cardiac events relating to pneumococcal infection
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
CN103936842B (zh) * 2014-04-30 2016-03-23 重庆医科大学 肺炎链球菌溶血素突变体及其作为粘膜免疫佐剂的应用
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
ES2993430T3 (en) * 2014-11-21 2024-12-30 Univ Oklahoma Pneumolysin mutants and methods of use thereof
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
WO2018183475A1 (en) 2017-03-28 2018-10-04 Children's Medical Center Corporation A multiple antigen presenting system (maps)-based staphylococcus aureus vaccine, immunogenic composition, and uses thereof
MX2019015524A (es) 2017-06-23 2020-09-10 Univ Maryland Composiciones inmunogenicas.
IL281204B2 (en) 2018-09-12 2025-07-01 Affinivax Inc Multivalent pneumococcal vaccines
TWI852943B (zh) 2018-09-12 2024-08-21 美商兒童醫療中心公司 肺炎鏈球菌融合蛋白疫苗
EP4034157A1 (en) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR20230162797A (ko) * 2021-03-22 2023-11-28 스타맵 바이오로직스 (쑤저우) 씨오., 엘티디 뉴몰리신을 표적으로 하는 항원 결합 단백질 및 이의 용도
CN113264999B (zh) * 2021-04-29 2023-02-28 星济生物(苏州)有限公司 中和肺炎链球菌溶血素蛋白的抗原结合蛋白及其用途
AU2022342080A1 (en) 2021-09-09 2024-03-28 Affinivax, Inc. Multivalent pneumococcal vaccines
AU2022391752A1 (en) 2021-11-18 2024-06-13 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
WO2025193903A1 (en) 2024-03-15 2025-09-18 Affinivax, Inc. Pneumococcal polysaccharide compositions and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US6716432B1 (en) * 1988-12-16 2004-04-06 James Cleland Paton Pneumolysin mutants and pneumococcal vaccines made therefrom
MC2178A1 (fr) * 1988-12-16 1992-05-22 Nederlanden Staat Mutants de la pneumolysine et vaccins a base de pneumocoque prepares a partir de ces mutants
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
WO1993013302A1 (de) 1991-12-23 1993-07-08 Michael Zoche Motor mit einer vorrichtung zur entölung
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
CN1257976C (zh) 1996-10-23 2006-05-31 宾夕法尼亚州立大学托管会 改良疫苗
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
AU740956B2 (en) * 1997-07-21 2001-11-15 Baxter Healthcare Sa Modified immunogenic pneumolysin compositions as vaccines
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
CA2792479A1 (en) 1998-02-27 1999-09-02 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
JP4673974B2 (ja) 1998-09-30 2011-04-20 ワイス・ホールディングズ・コーポレイション アジュバントとしての変異コレラホロトキシン
CN1977971A (zh) 2001-06-07 2007-06-13 惠氏控股有限公司 作为佐剂的霍乱全毒素的突变体形式
IL159209A0 (en) 2001-06-07 2004-06-01 Wyeth Corp Mutant forms of cholera holotoxin as an adjuvant
UA93854C2 (ru) 2003-12-17 2011-03-25 Вайет Ллк Иммуногенный конъюгат и способ его получения

Also Published As

Publication number Publication date
SI1743027T1 (sl) 2013-10-30
CN101018863A (zh) 2007-08-15
PL1743027T3 (pl) 2013-11-29
JP4848552B2 (ja) 2011-12-28
CA2566344A1 (en) 2005-11-17
CN101018863B (zh) 2012-01-04
EP1743027B1 (en) 2013-07-10
IL203479A (en) 2013-04-30
GB0410220D0 (en) 2004-06-09
KR101191591B1 (ko) 2012-10-15
AU2005240835B2 (en) 2011-12-01
WO2005108580A1 (en) 2005-11-17
ES2427978T3 (es) 2013-11-05
KR20070073602A (ko) 2007-07-10
JP2008505617A (ja) 2008-02-28
AU2005240835A1 (en) 2005-11-17
CA2566344C (en) 2015-07-07
US7820789B2 (en) 2010-10-26
IL178885A (en) 2011-11-30
EP1743027A1 (en) 2007-01-17
US20080112964A1 (en) 2008-05-15
IL178885A0 (en) 2007-03-08
PT1743027E (pt) 2013-10-08

Similar Documents

Publication Publication Date Title
GB0410220D0 (en) Mutant pneumolysin proteins
DE50310628D1 (de) Erfahren
DK1699821T3 (da) Fc-ERYTHROPOIETIN-FUSIONSPROTEIN MED FORBEDREDE FARMAKOKINETIKKER
DE602005025468D1 (de) Gssystem
DE602005021602D1 (de) Neigungsverstellvorrichtung
ITMI20041571A1 (it) Perfluoroelastomeri
DK1804871T3 (da) Forbedret mellemstykke
DE602005023894D1 (de) Rücklehnvorrichtung
DK1809660T3 (da) Thymus-specifikt protein
GB0423974D0 (en) Proteins
ATE521769T1 (de) Beschlag
DE60322439D1 (de) Anschlussstück
ES1064684Y (es) Tapizado
DE502004000407D1 (de) Sitzmöbel
GB0423002D0 (en) Proteins
NO20040521A (no) Proteinutskiller
GB0401882D0 (en) Protein
SE0400209D0 (sv) Novel methods
ES1060725Y (es) Reclinalibros
ES1057547Y (es) Roldana mejorada
UA10445S (uk) Подушка
ES1057042Y (es) Conjunto anillo-pendientes
SE0400497D0 (sv) Artikulator
GB0411678D0 (en) Proteins
GB0415161D0 (en) Proteins